Biotech: Page 16
-
Marko Georgiev / Stringer via Getty Images
Merck, facing threat to Keytruda, buys into new kind of cancer immunotherapy
The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that recently bested Keytruda in a clinical trial.
By Ben Fidler • Nov. 14, 2024 -
Kimberly White/Getty Images via Getty Images
23andMe to lay off more than 200 employees amid business struggles
The genetic testing firm will also close its drug development arm. CEO Anne Wojcicki said the cuts are necessary to “focus on the long-term success of our core consumer business.”
By Ricky Zipp • Nov. 13, 2024 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.
By BioPharma Dive staff -
Daniel Tadevosyan via Getty Images
Amgen shares sink on obesity drug concerns; AstraZeneca to spend $3.5B on manufacturing
An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis struck drug discovery deals.
By BioPharma Dive staff • Nov. 13, 2024 -
Honglouwawa via Getty Images
Metsera raises $215M to accelerate obesity drug plans
With promising Phase 1 results in hand, Metsera hopes to develop a longer-lasting GLP-1 injection along with other types of obesity treatments.
By Kristin Jensen • Nov. 13, 2024 -
Permission granted by TRex Bio
TRex Bio raises $84M to compete in crowded immune drug field
The California biotech has drawn partnerships with Eli Lilly and J&J on the promise of its approach to rebalancing the immune system.
By Gwendolyn Wu • Nov. 13, 2024 -
Thomas Lohnes via Getty Images
BioNTech to buy Biotheus, gaining control of cancer bispecific
Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit Therapeutics’ ivonescimab.
By Jonathan Gardner • Nov. 13, 2024 -
Permission granted by Flagship Pioneering
GSK partners with Flagship startup to hunt for Parkinson’s drugs
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for Parkinson’s and another neurodegenerative condition.
By Gwendolyn Wu • Nov. 12, 2024 -
koto_feja via Getty Images
Biotech investors, including Third Rock, pump $100M into a startup’s genetic medicine for ALS
Trace Neuroscience aims to advance an RNA-binding therapy designed to preserve — and potentially improve — muscle function in people living with the nerve-destroying disorder.
By Jacob Bell • Nov. 12, 2024 -
Nemes Laszlo via Getty Images
FDA approves new CAR-T competitor to Gilead’s Tecartus
Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the brand name Aucatzyl.
By Jonathan Gardner • Nov. 11, 2024 -
Sarah Silbiger via Getty Images
FDA lifts pause on Novavax flu vaccine trials
After an investigation, the agency concluded that a case of muscle weakness in one of Novavax’s trials was actually ALS and unrelated to vaccination.
By Delilah Alvarado • Nov. 11, 2024 -
Permission granted by Cullinan Therapeutics
Sponsored by Cullinan TherapeuticsFueling accelerated drug development in autoimmune diseases with a modality-agnostic approach
Innovation-without-borders philosophy seeks to bring forward only the most promising therapies.
By Cullinan Therapeutics • Nov. 11, 2024 -
Shutterstock/Ad_hominem
Sponsored by LabConnect7 steps to selecting the right global central lab
Unlock global clinical trial success with seamless sample logistics and standardized testing.
Nov. 11, 2024 -
JaysonPhotography via Getty Images
Kalaris to go public via reverse merger with AlloVir
After Kalaris and AlloVir combine, the new company will have about $100 million to advance a treatment for age-related macular degeneration.
By Delilah Alvarado • Updated Nov. 8, 2024 -
Daniel Tadevosyan via Getty Images
Tezspire succeeds in chronic rhinosinusitis; Gilead writes down Trodelvy value
AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a narcolepsy drug and CDMO Avid Bioservices agreed to be taken private.
By BioPharma Dive staff • Nov. 8, 2024 -
selvanegra via Getty Images
Athira exploring strategic alternatives after Alzheimer’s failure
On the heels of its most advanced medicine flunking a key study, the drugmaker is looking at the different paths it could take to “maximizing stockholder value.”
By Jacob Bell • Nov. 8, 2024 -
Jacob Bell/BioPharma Dive
Moderna earnings beat forecasts, but analysts question whether sales spike will last
Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.
By Ned Pagliarulo • Nov. 7, 2024 -
Jacob Bell/BioPharma Dive
Sarepta scraps a Duchenne drug as gene therapy sales rise
Elevidys sales have increased since the FDA made a controversial choice to expand the therapy's use. Meanwhile, Sarepta is abandoning a successor to its drug Exondys 51, citing an “evolving" treatment landscape.
By Kristin Jensen • Nov. 7, 2024 -
Chip Somodevilla via Getty Images
With Trump victorious, biotech industry’s focus turns to his plans for FDA, FTC
The president-elect has said he’ll let Robert F. Kennedy Jr. “go wild” on healthcare, while many expect a leadership change at the FTC could lower M&A scrutiny.
By Ned Pagliarulo , Ben Fidler • Nov. 7, 2024 -
Daniel Tadevosyan via Getty Images
Moderna said to shuffle sales leadership; Vertex records first Casgevy sale
Stephen Hoge will now oversee vaccine sales at Moderna, per a Bloomberg report. Elsewhere, Intra-Cellular unveiled an ambitious sales target and Syndax inked a lucrative royalty deal.
By BioPharma Dive staff • Nov. 6, 2024 -
Jacob Bell/BioPharma Dive
Emerging biotechAn RNAi renaissance is creating a new generation of startups
Pioneers like Alnylam Pharmaceuticals have led the RNA interference field for years. Now, a crop of young biotechs is building on that foundation by taking the drugmaking technology in new directions.
By Gwendolyn Wu • Nov. 6, 2024 -
Peddalanka Ramesh Babu via Getty Images
Cancer cell therapy from Arcellx, Gilead shows promise in early data
The companies’ CAR-T seemed to cause fewer movement disorders in a multiple myeloma trial than J&J's Carvykti has in other tests, although Wall Street analysts were divided on how the two drugs compare.
By Jonathan Gardner • Nov. 5, 2024 -
Dr_Microbe via Getty Images
Sickle cell patient dies in Beam study of base editing therapy
The death, which investigators linked to a preparatory chemo treatment rather than Beam's medicine, highlights the risks of using decades-old transplant drugs alongside cutting-edge CRISPR medicines.
By Ned Pagliarulo • Nov. 5, 2024 -
Permission granted by Rallybio
Two former Alexion leaders fight through a tough market to sustain a rare disease biotech
Rallybio is headed into a mid-stage trial with enough cash to last it through 2026, but biotech's down market has made the company's journey difficult.
By Michael Gibney • Nov. 5, 2024 -
Maximusnd via Getty Images
Neurogene secures $200M ahead of anticipated study readout
The news led to a stock surge on expectations that forthcoming data for the company’s experimental gene therapy for Rett syndrome may turn out positive.
By Delilah Alvarado • Nov. 4, 2024 -
ShutterStock/Chepko Danil Vitalevich
Sponsored by Bio-RadEmpowering versatile applications of digital PCR with standardized, validated assays
Bio-Rad’s extensive ddPCR assay offerings help researchers leverage the full power of digital PCR.
Nov. 4, 2024
Previous
